FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
about
Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on AsparaginaseAsparaginase pharmacokinetics and implications of therapeutic drug monitoringUncoupling Intramolecular Processing and Substrate Hydrolysis in the N-Terminal Nucleophile Hydrolase hASRGL1 by Circular PermutationAdvances in the use of nanocarriers for cancer diagnosis and treatmentSynthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexesEffectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.Assessment of Obesity and Hepatic Late Adverse Effects in the Egyptian Survivors of Pediatric Acute Lymphoblastic Leukemia: a Single Center Study.Next generation delivery system for proteins and genes of therapeutic purpose: why and how?Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginaseL-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginaseArginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.Targeted Mesoporous Iron Oxide Nanoparticles-Encapsulated Perfluorohexane and a Hydrophobic Drug for Deep Tumor Penetration and TherapyDe novo engineering of a human cystathionine-γ-lyase for systemic (L)-Methionine depletion cancer therapy.Advances in paediatric cancer treatmentAllergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.High-throughput asparaginase activity assay in serum of children with leukemiaEfficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphomaFirst-line treatment of acute lymphoblastic leukemia with pegasparaginase.A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma.Peg-asparaginase for acute lymphoblastic leukemia.Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.Targeting methionine auxotrophy in cancer: discovery & exploration.Erwinia asparaginase in pediatric acute lymphoblastic leukemia.Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.Nanooncology: the future of cancer diagnosis and therapy.A critical review on properties and applications of microbial l-asparaginases.Clinical study of l-asparaginase in the treatment of extranodal NK/T-cell lymphoma, nasal type.Therapeutic l-asparaginase: upstream, downstream and beyond.Surface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges.Asparaginase pharmacology: challenges still to be faced.Bioengineered arginase I increases caspase-3 expression of hepatocellular and pancreatic carcinoma cells despite induction of argininosuccinate synthetase-1.Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.Cerebral Sinus Venous Thrombosis due to Asparaginase Therapy.Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications
P2860
Q26784116-7A98747E-251A-408F-80B8-1D593B9112F5Q27026476-EEA23578-2E5E-4938-BB7E-C72BE193F7F5Q27671536-26A904A8-4F17-4B74-BA75-C9F7F21220EEQ28070065-941FFF80-93B6-429B-BD6C-0D48766FECFCQ30358389-C6D92FCA-F8C6-4031-9132-54F9B3A93E84Q33415901-23BCDA24-E6D2-4176-AF8E-A25944E18BF0Q33423016-F83EC05D-A64A-47A0-9D27-A4E8E3F25479Q33642238-B8A3F577-EF6D-4DCF-AAF2-549DCDC06DD4Q34003800-022C53AB-1E32-4AD3-A7C6-1923903F4371Q34064049-F063B53D-DA81-4511-BBB3-4C9828B6516FQ34400424-AD4BD67C-B77C-4C5C-9B31-7B02431F9996Q35561304-8127F296-0674-460E-BCE9-E7257B53B0CBQ35667279-9D5E72E1-E28B-4915-A4A9-358A0E26CD87Q35803555-1B3467E2-2807-447A-95DA-917B65FDACEDQ36056206-898E5694-63EB-49C9-BDBD-F10693A2C038Q36405822-72E21E52-3981-4CE2-A143-DDA829F63BDDQ36508630-4191B1F9-B7A5-4364-9D5D-FC34886C39C2Q36697877-AB80D903-4FE6-4C79-9690-93A9589267DBQ36762608-6D3D9D6C-4643-4EE0-9A09-1154EE4405CCQ37063860-0AC6FF96-DE65-4ACE-8475-015890808FC9Q37301747-1A634FEE-320D-4138-AA9C-E972CFF9D089Q37376566-DD863A48-8A01-4575-A0B9-863252F15DFCQ37586935-8B96811A-77DC-40C3-9D63-4F07893E3A89Q37670065-E062D082-50FD-4A34-A1D2-2D1ADD4B1D1FQ37697320-11350281-9EAA-4C91-806E-327088EF3160Q37719558-DE788545-3E37-4645-9637-48C66646804BQ37914185-732B6767-3A70-48AC-B1D3-0BBE94ED61A2Q37968630-853AC1C6-65FD-42D5-BCEF-067C7087C7A1Q38040418-30927B0F-BE04-4EEB-862D-46E11707B0F7Q38079075-88476D08-FB62-4851-B518-660C9A9383D7Q38151549-F9962828-4CDA-4819-B3DC-90A562BD2254Q38417141-919F3995-218D-4EBE-8D34-6502C4834303Q38433407-C1A2E25D-0CB4-4E88-BE12-4320C2512756Q38676439-6323670F-9DBF-431D-9EFF-762FAF066E36Q38899902-1AA00411-1C42-4E05-B260-D779C22D89D7Q39135887-9DA4AB40-D578-411D-BFD4-3CA3B9672182Q39704277-B4ED8F0B-104E-4AC2-922A-B32108DD4480Q40441775-0A0F0D3D-AAAC-4946-8B74-54CFC0FAE532Q41789033-2E52D6C7-9EB6-4B14-B3BE-A191A0558B0FQ42175440-27A571D0-584F-42B7-8431-194681B07AC9
P2860
FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
FDA drug approval summary: peg ...... lymphoblastic leukemia (ALL).
@en
FDA drug approval summary: pegaspargase
@nl
type
label
FDA drug approval summary: peg ...... lymphoblastic leukemia (ALL).
@en
FDA drug approval summary: pegaspargase
@nl
prefLabel
FDA drug approval summary: peg ...... lymphoblastic leukemia (ALL).
@en
FDA drug approval summary: pegaspargase
@nl
P2093
P1433
P1476
FDA drug approval summary: peg ...... lymphoblastic leukemia (ALL).
@en
P2093
Joseph Gootenberg
Martin H Cohen
Patricia Anne Dinndorf
Patricia Keegan
Richard Pazdur
P304
P356
10.1634/THEONCOLOGIST.12-8-991
P577
2007-08-01T00:00:00Z